From Financial Modeling Prep: 2025-06-16 17:02:00

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) faces stock price drop post patient death related to ELEVIDYS treatment. However, company’s product revenue grows by 70%, showing business strength. Market cap at $1.96 billion, trading volume of 30,136,821 shares, suggesting stock may be oversold. Long-term investors may view this as an opportunity to invest at lower levels.



Read more at Financial Modeling Prep:: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Faces Cha…